Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort.
about
Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression ModelManagement of low (favourable)-risk prostate cancerLow serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance.Benchmarks for operative outcomes of robotic and open radical prostatectomy: results from the Health Professionals Follow-up StudyPathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort.Active surveillance for prostate cancer: patient selection and management.Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer.Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification.Watchful waiting and quality of life among prostate cancer survivors in the Physicians' Health Study.Gleason score 6 adenocarcinoma: should it be labeled as cancer?Active surveillance for prostate cancer: an underutilized opportunity for reducing harm.An economic analysis of conservative management versus active treatment for men with localized prostate cancerLow prostate-specific antigen and no Gleason score upgrade despite more extensive cancer during active surveillance predicts insignificant prostate cancer at radical prostatectomy.Utility of 5-alpha-reductase inhibitors in active surveillance for favourable risk prostate cancerThe potential impact of comparative effectiveness research on U.S. health care expenditures.When is active surveillance the appropriate treatment for prostate cancer?Effect of delaying surgery on radical prostatectomy outcomes: a contemporary analysis.Senescent remodeling of the innate and adaptive immune system in the elderly men with prostate cancer.Expectant management for men with early stage prostate cancer.Physicians' Perceptions of Factors Influencing the Treatment Decision-making Process for Men With Low-risk Prostate Cancer.Tumor angiogenesis as an early marker of long-term prostate cancer mortality.[Effects of modified inclusion criteria and negative reporting about PSA screening on the number of potentially recruitable patients for the PREFERE study].Sociodemographic and Clinical Predictors of Switching to Active Treatment among a Large, Ethnically Diverse Cohort of Men with Low Risk Prostate Cancer on Observational Management.Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer.Prostate cancer and the increasing role of active surveillance.Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study.Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.Prevention of Prostate Tumor Development by Stimulation of Antitumor Immunity Using a Standardized Herbal Extract (Deep Immune®) in TRAMP Mice.
P2860
Q26783861-838AA177-5ED6-4785-A2F9-CFD6B10EBCEEQ26996501-E2E4A3A2-3212-45A4-B075-172850D19503Q33566981-297D2CD4-4EAA-4B96-A2AB-57C88FBCEDD4Q34028700-D0405DD2-D0FF-429E-B2BD-8F73AC2BF40CQ34076949-F5E4A723-708C-4482-8A1E-C73923CCDAB1Q34111584-E70A67BC-0880-4C12-95B8-695427AFF36FQ34407351-A09E98E3-52BE-40C7-99F8-605782A3356FQ35471903-62B21D2A-10BD-4FF7-8ECC-4825961BC38AQ36378954-85DA3743-80ED-43B6-81C3-6690706C9B22Q36449197-29CEC703-F27D-4C6D-BD4A-CA0F233C4FF1Q36520443-D86D5522-7C12-4BBC-840A-B447F26A7580Q36520468-D49E87D0-3E3B-4EBB-8215-F4F672FB679CQ37023829-B0055BEA-C49D-4AF4-82F7-8BF967FB7474Q37421848-2AAAE234-A2FC-4752-BED7-E15AC3E2A708Q37837744-BB309A53-79FF-41A7-869D-879F59FCF656Q37878475-8C71F644-134E-4C87-B0DC-93CCCFE30D39Q37957382-F8CE058D-C909-4238-8629-E727AA459479Q38207592-15439944-CB0E-47D5-87AA-1D464BBB8E63Q38469754-C7780365-4D60-4706-9155-9DF8552382D5Q38813806-2BF605EC-C8D3-496A-823C-5F24D4E5959CQ39892850-207D2D65-ACBB-4C8A-BC7E-496067228031Q40616371-A5ED8CC4-2A04-4AA1-B734-9168BAF4E1E2Q41662619-1C6E26B0-B64E-4B47-94D8-C7F96D2906D7Q42265374-DCEEFF35-81D8-4F37-9325-B6A74B3E5A17Q46054276-8159E02A-C215-4789-B576-F23E5B74D85DQ51248430-F16AE484-520F-4470-A694-96E436C84A07Q53292172-1A4158F3-F28C-403D-BB40-B63B18E6FBF4Q55401425-4E3D89EE-4C5E-4112-817C-F42F04A24502
P2860
Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Prospective study of determina ...... cancer in a nationwide cohort.
@ast
Prospective study of determina ...... cancer in a nationwide cohort.
@en
Prospective study of determina ...... cancer in a nationwide cohort.
@nl
type
label
Prospective study of determina ...... cancer in a nationwide cohort.
@ast
Prospective study of determina ...... cancer in a nationwide cohort.
@en
Prospective study of determina ...... cancer in a nationwide cohort.
@nl
prefLabel
Prospective study of determina ...... cancer in a nationwide cohort.
@ast
Prospective study of determina ...... cancer in a nationwide cohort.
@en
Prospective study of determina ...... cancer in a nationwide cohort.
@nl
P2093
P2860
P356
P1476
Prospective study of determina ...... cancer in a nationwide cohort.
@en
P2093
Julie L Kasperzyk
June M Chan
Martin G Sanda
Stacey A Kenfield
William V Shappley
P2860
P304
P356
10.1200/JCO.2008.21.2613
P407
P577
2009-08-31T00:00:00Z